Trinity Biotech (TRIB) faces Nasdaq compliance deadline over $15M MVPHS rule

Rhea-AI Filing Summary

Trinity Biotech plc received a Nasdaq notice that it no longer meets the Nasdaq Global Select Market requirement that listed securities maintain a minimum market value of publicly held shares of $15,000,000 based on the last 30 consecutive business days.

The company’s ADSs remain listed and trading on the Nasdaq Global Select Market under the symbol TRIB, with no immediate effect from the notice. Trinity Biotech has 180 calendar days, until August 18, 2026, to regain compliance by having its market value of publicly held shares exceed $15,000,000 for at least 10 consecutive business days, or it may seek transfer to The Nasdaq Capital Market if it meets those listing standards.

If it fails to regain compliance or transfer by that date, Nasdaq may move to delist the ADSs, a decision the company could appeal to a hearings panel, though success is not assured.

Positive

• None.

Negative

• Nasdaq listing deficiency and potential delisting over MVPHS shortfall: Trinity Biotech no longer satisfies Nasdaq Global Select Market Rule 5450(b) requiring a minimum $15,000,000 market value of publicly held shares and faces possible delisting if it cannot regain compliance or transfer to The Nasdaq Capital Market by August 18, 2026.

Insights

Equity listing and capital markets analyst

Nasdaq listing deficiency introduces delisting risk if compliance is not restored.

Trinity Biotech has been notified by Nasdaq that its market value of publicly held shares has stayed below $15,000,000 for 30 consecutive business days, breaching Listing Rule 5450(b). The ADSs continue to trade on the Nasdaq Global Select Market for now.

Under Listing Rule 5810(c)(3)(D), the company has 180 calendar days, until August 18, 2026, to push its MVPHS above $15,000,000 for at least 10 consecutive business days or qualify to transfer to The Nasdaq Capital Market. If it does neither, Nasdaq may initiate delisting.

Any delisting notice after August 18, 2026 could be appealed to a hearings panel, but the company notes there is no assurance an appeal would succeed. Actual impact will depend on future MVPHS levels, potential market transfer, and any panel outcome.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232, 333-253070 and 333-292753).

 EXPLANATORY NOTE

On February 19, 2026, the Company issued a press release announcing it had received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000, based on Nasdaq’s review of the Company’s MVPHS for the last 30 consecutive business days. The Company has a period of 180 calendar days, or until August 18, 2026 to regain compliance with Nasdaq Listing Rule 5450(b). A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ Paul Murphy
		Paul Murphy
		Interim Chief Financial Officer

Date:  February 20, 2026

Exhibit 99.1

Contact:	Trinity Biotech plc	RedChip Companies Inc.
	Paul Murphy	Dave Gentry, CEO
	(353)-1-2769800	(1)-407-644-4256
		(1)-800-RED-CHIP (733-2447)
		TRIB@redchip.com

Trinity Biotech Receives Non-Compliance Notice Regarding

Nasdaq Global Select Requirement for Minimum Market Value of

Publicly Held Shares

DUBLIN, Ireland (February 20, 2026) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000, based on Nasdaq’s review of the Company’s MVPHS for the last 30 consecutive business days.

This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days, or until August 18, 2026, to regain compliance with the MVPHS requirement. To regain compliance, the Company’s MVPHS must exceed $15,000,000 for a minimum of 10 consecutive business days. In the event that the deficiency continues for 180 days, the Company may seek to apply for a transfer to The Nasdaq Capital Market exchange if it meets the requirements for continued listing thereon. If the Company does not regain compliance with the minimum MVPHS requirement by August 18, 2026 or transfer to The Nasdaq Capital Market, Nasdaq will provide written notification to the Company that its ADSs are subject to delisting. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful.

Forward-Looking Statements

This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

FAQ

What Nasdaq rule did Trinity Biotech (TRIB) fail to meet?

Trinity Biotech failed Nasdaq Listing Rule 5450(b), which requires a minimum market value of publicly held shares of $15,000,000. Nasdaq determined the company’s MVPHS stayed below this threshold for 30 consecutive business days, triggering the non-compliance notice.

Does the Nasdaq non-compliance notice immediately affect Trinity Biotech ADS trading?

The notice has no immediate effect on trading of Trinity Biotech’s ADSs. They continue to trade on the Nasdaq Global Select Market under the symbol TRIB while the company works within Nasdaq’s 180-day compliance period ending August 18, 2026.

How can Trinity Biotech (TRIB) regain compliance with Nasdaq MVPHS requirements?

To regain compliance, Trinity Biotech’s market value of publicly held shares must exceed $15,000,000 for at least 10 consecutive business days within the 180-day period ending August 18, 2026, in accordance with Nasdaq Listing Rule 5810(c)(3)(D).

What happens if Trinity Biotech does not regain Nasdaq compliance by August 18, 2026?

If Trinity Biotech does not regain compliance or transfer to The Nasdaq Capital Market by August 18, 2026, Nasdaq will notify the company that its ADSs are subject to delisting. The company could then appeal to a hearings panel, with no assurance of success.

Can Trinity Biotech move from Nasdaq Global Select to Nasdaq Capital Market?

If the MVPHS deficiency persists for 180 days, Trinity Biotech may seek transfer to The Nasdaq Capital Market. Any transfer would depend on meeting that market’s continued listing requirements, as outlined in the company’s explanation of the Nasdaq process.

What business does Trinity Biotech (TRIB) operate while addressing Nasdaq issues?

Trinity Biotech is a commercial-stage biotechnology company focused on diabetes management and human diagnostics. It develops and markets diagnostic systems and wearable biosensors, including continuous glucose monitoring products, selling in the United States and through partners in over 75 countries.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 10.5 KB